Rafferty Asset Management
MRTX

Rafferty Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Rafferty Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-158,931
Closed -$9.34M – 1106
2023
Q4 		$9.34M Sell
158,931
-90,681
-36% -$5.1M 0.04% 298
2023
Q3 		$10.9M Buy
249,612
+30,973
+14% +$1.11M 0.06% 206
2023
Q2 		$7.9M Buy
218,639
+45,123
+26% +$1.86M 0.04% 285
2023
Q1 		$6.45M Sell
173,516
-19,557
-10% -$880K 0.04% 319
2022
Q4 		$8.75M Buy
193,073
+111,361
+136% +$7.21M 0.07% 223
2022
Q3 		$5.71M Buy
81,712
+17,048
+26% +$1.26M 0.06% 310
2022
Q2 		$4.34M Sell
64,664
-1,537
-2% -$97.7K 0.04% 306
2022
Q1 		$5.44M Buy
66,201
+27,070
+69% +$2.77M 0.03% 370
2021
Q4 		$5.74M Buy
39,131
+20,312
+108% +$3.15M 0.03% 325
2021
Q3 		$3.33M Buy
18,819
+3,658
+24% +$589K 0.02% 422
2021
Q2 		$2.45M Sell
15,161
-2,374
-14% -$381K 0.02% 617
2021
Q1 		$3M Buy
17,535
+13,623
+348% +$2.7M 0.02% 493
2020
Q4 		$859K Sell
3,912
-11,109
-74% -$2.4M 0.01% 544
2020
Q3 		$2.49M Buy
15,021
+5,700
+61% +$780K 0.03% 356
2020
Q2 		$1.06M Buy
9,321
+5,207
+127% +$505K 0.02% 526
2020
Q1 		$316K Sell
4,114
-30,837
-88% -$2.77M 0.01% 423
2019
Q4 		$4.5M Sell
34,951
-40,816
-54% -$3.94M 0.07% 145
2019
Q3 		$5.9M Buy
75,767
+23,314
+44% +$2.19M 0.09% 129
2019
Q2 		$5.4M Sell
52,453
-19,043
-27% -$1.48M 0.1% 145
2019
Q1 		$5.24M Buy
+71,496
New +$4.86M 0.08% 131

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rafferty Asset Management's MRTX Position: Q1 2024 in Review

Rafferty Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 158,931 shares — an estimated $9.34M sold.

Rafferty Asset Management first reported a position in MRTX in Q1 2019 and held it in 20 quarters. The position peaked at $10.9M in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Rafferty Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 158,931 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $9.34M.
  • Rafferty Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 20 quarters.
  • Rafferty Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $10.9M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Rafferty Asset Management's 13F filing for Q1 2024, filed 13 May 2024.